First-line treatment with rituximab-hyperCVAD alternating...

Haematologica 2013 / 10 Vol. 98; Iss. 10

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

Arranz, R., Garcia-Noblejas, A., Grande, C., Cannata-Ortiz, J., Sanchez, J. J., Garcia-Marco, J.-A., Alaez, C., Perez-Calvo, J., Martinez-Sanchez, P., Sanchez-Gonzalez, B., Canales, M.-A., Conde, E.,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
98
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2013.088377
Date:
October, 2013
File:
PDF, 478 KB
english, 2013
Conversion to is in progress
Conversion to is failed